Objective: We aimed to investigate whether reversible cerebral vasoconstriction syndrome (RCVS) could recur and to identify the potential predictors of recurrence in a large cohort of patients.
Reversible cerebral vasoconstriction syndrome (RCVS) is a disorder characterized by abrupt, severe headaches (mostly thunderclap headaches) and reversible segmental cerebral vasoconstrictions. 1 RCVS is not an uncommon clinical emergency, [2] [3] [4] but it is still underrecognized. 5 A substantial proportion of patients with RCVS experience devastating complications, such as posterior reversible encephalopathy syndrome, ischemic stroke, or intracranial hemorrhages, including cortical subarachnoid, intracerebral, and subdural hemorrhages. [2] [3] [4] [6] [7] [8] The pathogenesis of RCVS remains unclear; autonomic dysregulation, 9 oxidative stress, 10 and genetic predisposition 11 may have roles. RCVS is generally considered a monophasic disease, which is limited to a period of 3 months. 12 However, very rare case reports have shown that the recurrence of RCVS could be possible. 13, 14 In our previous study, 3 (5.4%) of 56 patients reported having previously experienced similar thunderclap headaches 3 months, 6 months, and 1 year before being diagnosed with RCVS. 2 In a follow-up study of a French cohort, 2 patients experienced a relapse of multiple thunderclap headaches 6 months and 3 years after the first bout of RCVS. 15 Although no angiographic studies were available for these prior or follow-up attacks, it is possible that these patients had recurrent RCVS. 2, 15 Considering the potentially hazardous effects of this disease, it is necessary to investigate in what proportion of patients and under what circumstances RCVS recurs after the first bout. To date, no prospective long-term study has examined the recurrence of RCVS. Therefore, the objective of this study was to investigate the recurrence of RCVS and its predictors in a large prospectively recruited cohort.
METHODS Participants and clinical settings. This study prospectively followed patients with RCVS from the headache center of Taipei Veterans General Hospital, a 2,909-bed national medical center in the capital of Taiwan, from December 2000 to December 2012. The diagnosis of RCVS was based on criteria shown in table 1. The criteria were adapted from the proposed diagnostic criteria of "benign (or reversible) angiopathy of the central nervous system" proposed by the International Classification of Headache Disorders, second edition (ICHD-2; code 6.7.3), 16 with the exception of the duration criterion D (i.e., headache [and neurologic deficits, if present] resolves spontaneously within 2 months), and the RCVS diagnostic elements proposed by Calabrese et al. 1 The criteria were also in concordance with the newly proposed criteria for "headaches attributed to RCVS" in the ICHD, third edition (beta version) 17 (ICHD-3b; code 6.7.3) (table 1) . In fact, all of our patients (n 5 210, 100%) fulfilled the new ICHD-3-b criteria.
Diagnostic evaluations and treatment for the first bout of RCVS. The diagnostic procedures and interventions have been reported elsewhere 6, 7 and are briefly summarized in table 2. All of the investigations were performed within the first 2 days after the patient was seen. Patients were placed on oral (30-60 mg every 4 hours) or IV (0.5-2 mg/h) nimodipine therapy with close blood pressure monitoring immediately after confirmation of cerebral vasoconstrictions and exclusion of all other possible causes of thunderclap headaches, especially aneurysmal subarachnoid hemorrhage. All patients were instructed to avoid triggers for thunderclap headaches before the resolution of vasoconstrictions.
All patients were regularly followed up at the headache clinic with gradual tapering of nimodipine if they were on it according to clinical symptoms. Sequential magnetic resonance angiography (MRA) and transcranial color-coded sonography (TCCS) were performed to ensure the reversibility of vasoconstrictions regarding both diagnosis and treatment. Mean flow velocity of middle cerebral artery (V MCA ) and the Lindegaard index (LI), 6 and the MRA vasoconstriction scores in the major intracranial arterial segments 7 were recorded. All patients were regularly seen at the headache clinic until there were no more thunderclap headache attacks and there was complete or at least marked resolution of the vasoconstrictions. This first bout of RCVS disease course was defined as initial RCVS.
Follow-ups. After remission of RCVS, the patients entered our follow-up program (figure 1). All patients were instructed to selfmonitor their headaches and neurologic symptoms, and received telephone follow-ups to assess their headache statuses. Some patients were followed up at our headache clinic on a regular basis for small lingering headaches or preexisting migraines that required medical attention. All patients were particularly instructed to return to our hospital immediately if they developed new headaches. If the new headaches were thunderclap headache-like, that is, acute severe attacks that reached maximum intensity immediately, then the patients underwent the same diagnostic evaluations as they did during their first bout of RCVS. The same diagnostic criteria as the first bout of RCVS (table 1) were also applied for the diagnosis of recurrent bouts of RCVS. Patients who were lost to follow-up 6 months after the onset of their first bout of RCVS were defined as nonrespondents, and patients who were able to respond to at least one telephone or headache clinic follow-up after 6 months were defined as respondents.
Standard protocol approvals, registrations, and patient consents. The study protocol was approved by the institutional review board of Taipei Veterans General Hospital. All participants provided written informed consent before entering the study. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit the research for publication.
Statistics. All analyses were performed with the IBM SPSS Statistics software package, version 18.0 (SPSS, Inc., Chicago, IL). Table 1 Diagnostic criteria of RCVS used in the current study and in the ICHD-3-b, code 6.7.3
Diagnostic criteria of RCVS used in the current study Descriptive statistics are presented as the mean 6 SD, median (range), or as the number (percentage). Student t, Fisher exact, or x 2 tests were used for comparisons between groups when appropriate. Paired t test or Wilcoxon signed-rank test was used to compare paired data. Cox regression model was used to determine variables independently associated with recurrence. All calculated p values were 2-tailed. Statistical significance was defined as a p , 0.05.
RESULTS
Patients and their characteristics. The RCVS cohort. We recruited 210 patients with RCVS during the 12-year study period (table e-1 on the Neurology ® Web site at Neurology.org). By the end of the study, 2 patients died of malignancies and 40 patients were lost to follow-up (nonrespondents). Hence, 168 patients (80.8%, respondents) were eligible for the final Figure 1 Diagram of patient enrollment and follow-up
Flowchart of follow-up for patients with reversible cerebral vasoconstriction syndromes (RCVS). The severity of vasoconstrictions on MRA was graded on a 5-point scale: 0 (0% to ,10%), 1 (10% to ,25%), 2 (25% to ,50%), 3 (50% to ,75%), and 4 ($75%), and designated the "vasoconstriction score" of each arterial segments for computations. The vasoconstriction scores of both sides were averaged to derive a mean score. The mean scores of different arterial segments were averaged to derive a combined score.
analysis (figure 1). The mean follow-up period of the respondents was 37.5 6 24.4 (median 31.6, range 6-131) months, and the cumulative follow-up duration was 525 person-years. Notably, 2 of the patients were sisters. The characteristics of the patients with RCVS are summarized in table e-1. There were no significant differences in the demographic and clinical characteristics between the respondents and nonrespondents, except that the respondents had a higher percentage of diabetes mellitus than the nonrespondents (6% vs 0%, p 5 0.001).
Patients with recurrent RCVS. Of the 168 respondents, 18 (10.7%) returned to our headache clinic or emergency department for the occurrence of new thunderclap-like headaches. Nine (5.4%) of the 168 patients were confirmed to have recurrent RCVS, which occurred a mean of 40.9 6 27.2 (median 35, range 6-87) months after the first bout (table e-2). The incidence rate was 1.71 per 100 personyears (95% confidence interval [CI] 1.68-1.75). Eight of these 9 patients were female (89%). Of the 9 patients, the first bout of RCVS occurred at a mean age of 50.2 6 4.7 years, and the recurrent bout occurred at a mean age of 53.8 6 5.8 years. Two (22%) of the 9 patients had hypertension, and 3 (33%) had migraine. None of the patients with recurrent RCVS had identifiable secondary causes for their first bout of RCVS, but one patient experienced the second bout of RCVS after taking magnesium lithospermate B, an extract of a traditional Chinese medicine Danshen (Salvia miltiorrhiza) (case 9). None of these patients developed complications, such as posterior reversible encephalopathy syndrome, ischemic stroke, or intracranial hemorrhages, during their first or recurrent bout of RCVS. The numbers and durations of thunderclap headaches did not differ between the first and recurrent bouts (p 5 0.179 and p 5 0.283, respectively, paired t test). During their first bouts, 7 patients (78%) reported at least one trigger for their thunderclap headaches. During the recurrent bouts, all patients had at least one identifiable trigger (table e-2).
During either the first or recurrent bout, the headaches were all explosive at onset with severe intensity (numerical rating scale score was 10 in 8 patients and 8 in 2 patients). The headaches were most frequently bilateral (78%) and involved the occipital regions (61%). The associated symptoms in these patients were similar between the first and recurrent bouts. None of the patients had neck stiffness. All 9 patients were treated with nimodipine for both bouts, with a response (i.e., no further thunderclap headaches within 48 hours) of 78% (7/9) during the first bouts and 67% (6/9) during the recurrent bouts.
Neuroimaging findings. The patients received multiple MRI studies during either the first or the recurrent bouts. The MRI findings did not demonstrate any intracranial lesions in any of the patients during either the first or the recurrent bouts. Except for vasoconstrictions, MRA and venography did not disclose any vascular abnormalities, including arterial aneurysms. The severity of vasoconstriction (in the first bout) in patients with recurrent RCVS (n 5 9) did not differ from that in patients without recurrence (n 5 159) (maximum V MCA : 104.8 6 27.9 vs 99.8 6 40.0 cm/s, p 5 0.726; maximum LI: 2.14 6 0.41 vs 2.24 6 0.89 cm/s, p 5 0.775). All patients had multisegmental arterial stenosis according to the MRA during both bouts (figure 2). The TCCS was performed on the same day as the MRA, and the maximum mean vasoconstriction score, V MCA , and LI are shown in table e-2. There was no difference in the combined vasoconstriction score 7 between the first and recurrent bouts (p 5 0.213, Wilcoxon signed-rank test).
Risk factors for recurrent RCVS. Clinical variables including demographics, medical illness, and headache triggers during the first bout of RCVS were assessed to see whether they could predict the recurrence of RCVS using a Cox regression model (table e-3). Univariate analysis showed that having sexual activities (hazard ratio 3.95, 95% CI 1.01-15.38, p 5 0.048) as a trigger for thunderclap headaches in the first bout of RCVS was an independent predictor for recurrent RCVS. The multivariable analysis showed that sexual activities as a trigger had a hazard ratio of 5.68 (95% CI 1.11-29.15, p 5 0.038).
Characteristics of patients who recurred with probable RCVS. Six patients (3.5%) with new thunderclap-like headaches were diagnosed with probable RCVS (figure 1) , which occurred a mean 48.2 6 30.1 (median 48, range 15-106) months after the previous bout with RCVS. For the remaining 3 patients who experienced new "thunderclap-like headache," 2 were diagnosed as acute migraine because their acute severe headaches actually reached peak intensity in around 10 to 15 minutes and fulfilled the diagnostic criteria of migraine. The headaches of the other patient were unclassified because the patterns of the headaches were inconsistent and poorly defined. The MRAs of all these 3 patients were negative. All the patients who recurred with probable RCVS were female, and their first bout of RCVS occurred at a mean age of 47.7 6 11.2 years. None of these patients had identifiable causes for their first bout of RCVS or the subsequent bout of probable RCVS. These patients were diagnosed with probable RCVS because their MRA (2 examinations in 4 patients and 1 examination in 2 patients) and TCCS (2 examinations in 3 patients and 1 examination in 3 patients) results showed no significant vasoconstriction. DISCUSSION In this prospective long-term followup study of a large cohort of patients with RCVS, we found that 5% of the patients had recurrent RCVS with an incidence rate of 1.71 per 100 person-years (95% CI 1.68-1.75). These results conflict with the common notion that RCVS is a monophasic disease. The chance of recurrent RCVS was high (50%) in patients who developed new thunderclap-like headaches. Having sexual activity as a trigger for thunderclap headaches was the only risk factor found for recurrent RCVS. The recurrent bouts of RCVS were not associated with higher rates of complications. None of our patients developed aneurysmal subarachnoid hemorrhage.
We found that recurrence of RCVS could happen as early as 6 months and as late as 7 years after the first bout. In the 2 previously reported cases of recurrent RCVS, 13, 14 one had recurrent postpartum angiopathy that occurred 32 months after the first bout, 14 and the other experienced a relapse after tapering therapy during a 43-month follow-up period (the exact timing of the relapse was not reported). 13 Hence, although the risk of RCVS recurrence was not high, it could not only be imminent after tapering treatment, but also be long-lasting. The occurrence of new thunderclaplike headaches should be considered as the most alarming symptom of RCVS recurrence. Once new thunderclap-like headaches occur, thorough investigations must be performed again. The characteristics of patients with recurrent RCVS were not distinctly different from the entire RCVS cohort; however, if the patients had sexual activity as a trigger during their first bout, a higher risk of recurrence should be warned. In the era before knowing that RCVS is an important cause for sexual headaches (now coded as 4.3 primary headache associated with sexual activity in the ICHD-3-b), patients with recurrent sexual headaches were usually treated as having a new episode of primary headache associated with sexual activity. If the patients have received comprehensive neurovascular investigations that disclose reversible vasoconstrictions, these patients should be diagnosed as having recurrent RCVS instead of recurrent primary headache associated with sexual activities. In addition, although not identified in our series, 2 historical cases with recurrent RCVS had hemorrhagic complications during their first bouts. 13, 14 Patients with hemorrhagic complications may need a prolonged follow-up.
The possibility of recurrence suggests that patients with RCVS might have a higher susceptibility to this disease. Yet, there has been no direct evidence in support of this speculation. In our heart rate variability study on patients with RCVS, 9 the sympathetic overactivity and parasympathetic hypofunction did not completely normalize after remission of RCVS, which suggests that patients with RCVS may carry a trait for disease susceptibility. The functional Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) was associated with the severity of RCVS, which suggests that there might be some genetic traits, especially on the more severe end of the disease spectrum. 11 However, whether this genetic variant could also have a role in the recurrence of RCVS is unknown because not all of the patients received BDNF Val66Met genotyping. In addition, a high heritability and liability of recurrence in preeclampsia, 18 a spectral disorder of RCVS, might be supportive of this hypothesis.
The RCVS patient cohort collected from our headache clinic largely consisted of patients with RCVS without identified etiologies. In the 9 patients with recurrent RCVS, one patient who had no identifiable causes for her first bout of RCVS experienced recurrent RCVS after ingestion of a plant extract. In the 2 previously reported cases with recurrence of thunderclap headaches but without angiographic studies, the recurrence was attributable to the use of vasoactive drugs. 15 Hence, although the evidence is still insufficient, the risk of recurrence after exposure to the secondary causes may be high. Clinicians should instruct patients to avoid reexposure to vasoactive substances upon the diagnosis of RCVS.
Our study had limitations. First, not all the recruited subjects returned to our headache clinic and responded to our follow-up telephone interviews after remission of the first bout. Nevertheless, the response rate of 80.8% was high for such a long study period, and the similar demographic and clinical characteristics between respondents and nonrespondents suggest that the current samples are representative. Second, it is possible that patients who recurred with probable RCVS did have vasoconstrictions, but the vasoconstrictions were not detected at the time of MRAs (e.g., the vasoconstrictions were still restricted to the distal arterioles beyond the resolution of MRA). Therefore, the incidence of RCVS recurrence might be somewhat higher than estimated. As such, even if initial angiographic studies do not disclose obvious vasoconstrictions in patients with "probable" recurrence of RCVS, these patients should still be considered "clinically" as patients with RCVS. Third, the proportions of patients who developed severe complications in our cohort were lower than those reported in Western countries. In addition, despite that the proportion of patients with focal neurologic deficits (8.9% vs 10%, p 5 0.766) or any MRI abnormalities (8.9% vs 15%, p 5 0.251) was similar between the respondents and nonrespondents, 2 patients with asymptomatic cortical subarachnoid hemorrhage and one-third (n 5 4) of the patients with ischemic stroke were lost to follow-up. Our study results might not be generalizable to other ethnic populations. Lastly, we used "at least 2 thunderclap headaches" as one criterion for the diagnosis of RCVS. We might have missed some patients with single thunderclap headache but apparent vasoconstrictions. However, according to previous studies including ours, 2-4,7 the chance should be rare.
Comment: Reversible cerebral vasoconstriction syndrome can hit twice
Rare cases with recurrent reversible cerebral vasoconstriction syndrome (RCVS) have been published. The authors analyzed the recurrence risk of RCVS in a large Taiwanese cohort; 210 patients with a definite RCVS were followed up during a mean period of about 3 6 2 years, with slightly less than 20% of cases lost to follow-up, leaving 168 patients for the final analysis. 1 The main result is that RCVS can hit twice. Recurrence occurred in a minority of cases (9 of the 168 patients, 5%) with a delay from the first to the second bout ranging from 6 months to 7 years. All initial RCVS were idiopathic. Recurrent RCVS was idiopathic in 8 cases and triggered by a vasoactive drug in one. Both initial and recurrent RCVS were benign, namely, purely cephalalgic without any focal deficit, stroke, or brain edema. Having sexually triggered thunderclap headaches during the initial RCVS was an independent predictor of recurrence.
The observed 5% recurrence rate of RCVS within the first few years applies only to the study population, which included a vast majority of cases with idiopathic and purely cephalalgic RCVS. Follow-up studies of the US 2 and the French 3 cohorts are awaited to determine the recurrence risk in the more severe cases, namely, those in whom RCVS was associated with headache and cerebral lesions including brain edema, convexity hemorrhage, or parenchymal stroke, and those in whom RCVS occurred postpartum or after drug exposure. These results should be transmitted to our patients who are often very anxious after recovery from a first RCVS. The majority of patients do well, without recurrence during the first years. However, new thunderclap headaches after a first RCVS should raise suspicion of a recurrence, and prompt new parenchymal and arterial cerebral imaging. 
